The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial
Open accessAbstract
BACKGROUND: Pharmacologic treatment options for posttraumatic stress disorder (PTSD) are limited in number and effectiveness. Medications currently in use to treat PTSD were originally approved based on their efficacy in other disorders, such as major depression. Substantial research in PTSD suggests that increased activity of corticotropin releasing hormone (CRH)-containing circuits are involved in the pathophysiology of the disease. This Phase II trial aims to evaluate the efficacy of a CRH type 1 receptor (CRHR1) antagonist in the treatment of PTSD. METHODS/DESIGN: Currently untreated adult women, ages 18 to 65 years, with a primary psychiatric diagnosis of PTSD of at least 3 months' duration, are being enrolled in a parallel-group, double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of GSK561679, a novel CRHR1 receptor antagonist. GSK561679 (or matching placebo) is prescribed at a fixed dose of 350 mg nightly for six weeks. The primary trial hypothesis is that GSK561679 will reduce symptoms of PTSD, as measured by the Clinician-Administered PTSD Scale (CAPS), significantly more than placebo after six weeks of treatment. Putative biological markers of PTSD which may influence treatment response are measured prior to randomization and after five weeks' exposure to the study medication, including: fear conditioning and extinction using psychophysiological measures; variants of stress-related genes and gene expression profiles; and indices of HPA axis reactivity. In addition, the impact of PTSD and treatment on neuropsychological performance and functional capacity are assessed at baseline and after the fifth week of study medication. After completion of the six-week double blind treatment period, subjects enter a one-month follow-up period to monitor for sustained response and resolution of any adverse effects. DISCUSSION: Considerable preclinical and human research supports the hypothesis that alterations in central nervous system CRH neuronal activity are a potential mediator of PTSD symptoms. This study is the first to assess the efficacy of a specific antagonist of a CRH receptor in the treatment of PTSD. Furthermore, the biological and neuropsychological measures included in this trial will substantially inform our understanding of the mechanisms of PTSD. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT01018992.Registered 6 November 2009. First patient randomized 14 January 2010.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While this trial could not reveal a significant improvement of PTSD symptoms,”
From The HPA Axis as Target for Depression (2024) · cites this paper as [105]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Four Factor Index of Social Status [1975]
Hollingshead, A. B. (1975) · Cited by 7,840
Four Factor Index of Social Status
Paschou, R. (1975) · Cited by 6,989
Development and validation of a brief screening version of the Childhood Trauma Questionnaire
Bernstein, D. P., Stein, J. A., Newcomb, M. D., Walker, E., Pogge, D., Ahluvalia, T., Stokes, J., Handelsman, L., Medrano, M., Desmond, D., et al. (2003) · Child Abuse & Neglect · doi:10.1016/s0145-2134(02)00541-0 · Cited by 6,419
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024
Research works printed but not linked: 1
- First MB, Spitzer RL, Gibbon M, Williams JB: SCID-I/P, Version 20th edition. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient. 1995, New York: Biometrics Research Department, New York State Psychiatric Institute
Cited by
Post-traumatic stress disorder.
Yehuda, R., Hoge, C. W., McFarlane, A. C., Vermetten, E., Lanius, R. A., Nievergelt, C. M., Hobfoll, S. E., Koenen, K. C., Neylan, T. C., & Hyman, S. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.57 · Cited by 870
Self-citationThe Corticotropin-Releasing Factor Family: Physiology of the Stress Response
Deussing, J. M., & Chen, A. (2018) · Physiological Reviews · doi:10.1152/physrev.00042.2017 · Cited by 260
Is the HPA Axis as Target for Depression Outdated, or Is There a New Hope?
Menke, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00101 · Cited by 240
The hypothalamic-pituitary-adrenal axis in PTSD: Pathophysiology and treatment interventions
Dunlop, B. W., & Wong, A. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.10.010 · Cited by 242
Self-citationEmerging drugs for the treatment of anxiety
Murrough, J. W., Yaqubi, S., Sayed, S., & Charney, D. S. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1049996 · Cited by 164
Metadata
- Authors
- Dunlop, B. W., Rothbaum, B. O., Binder, E. B., Duncan, E., Harvey, P. D., Jovanovic, T., Kelley, M. E., Kinkead, B., Kutner, M., Iosifescu, D. V., Mathew, S. J., Neylan, T. C., Kilts, C. D., Nemeroff, C. B., & Mayberg, H. S.
- Affiliations
- Emory University (US)
- University of Miami (US)
- Icahn School of Medicine at Mount Sinai (US)
- Michael E. DeBakey VA Medical Center (US)
- San Francisco VA Medical Center (US)
- University of Arkansas for Medical Sciences (US)
- Corresponding author
- Dunlop, Boadie W
- ORCID
- Venue
- Trials
- Published
- 2014-06-21
- Volume
- 15
- Issue
- 1
- Pages
- 240-240
- ISSN
- 1745-6215 (ISSN-L)
- PMC
- PMC4082482
- OpenAlex
- W2130017328
- Cited by
- 45
- References
- 54
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 6 · 2017: 6 · 2016: 7 · 2015: 4 · 2014: 2
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Trials (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- Max Planck Digital Library (submittedVersion, other-oa)
- Funders
- U.S. Department of Veterans Affairs
- GlaxoSmithKline
- Neurocrine Biosciences
- National Institutes of Health (5u19mh069056-10)
- Clinical Science Research and Development
- National Institute of Mental Health (U19-MH069056, K23MH086690)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Social Sciences › Psychology › Clinical Psychology › Migration, Health and Trauma
- Keywords
- post-traumatic stress disorder, women, fear conditioning, fear extinction, stress-related genes, gene expression, HPA axis reactivity, neuropsychological performance, functional capacity, PTSD pharmacotherapy
- MeSH terms
- CRF Receptor, Type 1, Adolescent, Adult, Aged, Clinical Protocols, Conditioning, Psychological, Diagnostic Techniques, Endocrine, Double-Blind Method, Extinction, Psychological, Fear, Female, Hormone Antagonists, Humans, Hypothalamo-Hypophyseal System, Middle Aged, Oxadiazoles, Pituitary-Adrenal System, Psychiatric Status Rating Scales, Research Design, Stress Disorders, Post-Traumatic, Time Factors, United States, Treatment Outcome, Receptors, Corticotropin-Releasing Hormone, Gene Expression Profiling, Azabicyclo Compounds, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. https://app.cochat.ai/papers/10.1186/1745-6215-15-240
- The paper
- Dunlop, B. W., Rothbaum, B. O., Binder, E. B., Duncan, E., Harvey, P. D., Jovanovic, T., Kelley, M. E., Kinkead, B., Kutner, M., Iosifescu, D. V., Mathew, S. J., Neylan, T. C., Kilts, C. D., Nemeroff, C. B., & Mayberg, H. S. (2014). Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials. https://doi.org/10.1186/1745-6215-15-240
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.